Nuvectis Pharma
NVCT
12 hedge funds and large institutions have $6.34M invested in Nuvectis Pharma in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 2 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
9% more funds holding
Funds holding: 11 → 12 (+1)
3.53% less ownership
Funds ownership: 6.72% → 3.19% (-3.5%)
14% less capital invested
Capital invested by funds: $7.38M → $6.34M (-$1.04M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$250K |
| 2 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
+$249K |
| 3 |
Jane Street
New York
|
+$112K |
| 4 |
BWP
Baldwin Wealth Partners
Marion,
Massachusetts
|
+$106K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$56.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$4.41M |
| 2 |
VF
Virtu Financial
New York
|
-$93K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$11.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $2.64M | +$56.8K | +5,604 | +3% |
|
|
BWP
2
Baldwin Wealth Partners
Marion,
Massachusetts
| $1.89M | +$106K | +10,500 | +8% |
|
3
Geode Capital Management
Boston,
Massachusetts
| $459K | +$37K | +3,654 | +12% |
|
|
4
Millennium Management
New York
| $323K | +$250K | +24,667 | New |
|
|
EDRH
5
Edmond de Rothschild Holding
Chambesy,
Switzerland
| $322K | +$249K | +24,570 | New |
|
6
BlackRock
New York
| $178K | +$34.4K | +3,395 | +33% |
|
7
State Street
Boston,
Massachusetts
| $176K | +$17.2K | +1,700 | +15% |
|
8
Man Group
London,
United Kingdom
| $168K | – | – | – |
|
|
9
Jane Street
New York
| $145K | +$112K | +11,086 | New |
|
10
Morgan Stanley
New York
| $40.8K | +$28.5K | +2,814 | +935% |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $3K | -$11.2K | -1,109 | -82% |
|
12
Bank of America
Charlotte,
North Carolina
| $2.15K | +$1.54K | +152 | +1,267% |
|
13
Wells Fargo
San Francisco,
California
| $328 | – | – | – |
|
|
SM
14
Sabby Management
Miami Beach,
Florida
| – | -$4.41M | -587,452 | Closed |
|
|
VF
15
Virtu Financial
New York
| – | -$93K | -12,418 | Closed |
|
NVCT Hedge Fund Activity: Q1 2023 in Review
12 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q1 2023, worth a combined $6.34M — down 14% from $7.38M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new NVCT positions and 2 closed out — a net gain of 1 holder — while 7 added to existing stakes and 1 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $250K. The largest seller was Sabby Management, exiting entirely with an estimated $4.41M sold.
- 12 institutional investors held Nuvectis Pharma (NVCT) as of Q1 2023, up from 11 in Q4 2022.
- Funds reported $6.34M of Nuvectis Pharma stock for Q1 2023, down 14% quarter-over-quarter.
- 3 funds opened new Nuvectis Pharma positions in Q1 2023 and 2 closed out, a net change of +1 holder.
- The largest Nuvectis Pharma buyer in Q1 2023 was Millennium Management, an estimated $250K added.
- The largest Nuvectis Pharma seller in Q1 2023 was Sabby Management, an estimated $4.41M sold.
Based on aggregated 13F filings for Q1 2023.